uniQure N.V. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $165.00K.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was -$1.00K, a 102.56% decline year-over-year.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $50.00K, a 21.95% increase year-over-year.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $49.00K, a 72.47% decline from fiscal 2023.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $178.00K, a 7.88% increase from fiscal 2022.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $165.00K, a 13.01% increase from fiscal 2021.
- uniQure N.V. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $146.00K, a 40.65% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $165.00K 10-Q · filed 2026-05-05 | |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $49.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | |
| 2024-06-30 | $50.00K 10-Q · filed 2025-07-29 | |
| 2023-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $178.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $54.00K 10-Q · filed 2024-11-05 | $173.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $41.00K 10-Q · filed 2024-08-01 | $160.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $44.00K 10-Q · filed 2024-05-07 | $149.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $165.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $41.00K 10-Q · filed 2023-11-07 | $132.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $30.00K 10-Q · filed 2023-08-01 | $188.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $61.00K 10-Q · filed 2023-05-09 | $158.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $146.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $97.00K 10-Q · filed 2022-11-02 | $245.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $148.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $49.00K 10-Q · filed 2022-05-02 | $217.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $246.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $251.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $69.00K 10-Q · filed 2021-07-26 | $350.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $78.00K 10-Q · filed 2021-05-10 | $365.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $368.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $99.00K 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $84.00K 10-Q · filed 2020-07-30 | |
| 2019-03-31 | $81.00K 10-Q · filed 2020-04-29 | |
| 2018-12-31 | $65.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |